Calcium Acetate Shortage: What Providers and Prescribers Need to Know in 2026

Calcium acetate (brand names PhosLo, Phoslyra, Eliphos, Calphron) remains one of the most widely prescribed phosphate binders for ESRD patients on dialysis. While calcium acetate is not currently on the FDA's active drug shortage list as of 2026, clinical teams are increasingly fielding calls from patients unable to find it at their local pharmacy. This guide is designed to help nephrologists, PCPs, NPs, PAs, and dialysis center staff navigate availability challenges and manage patient care continuity.

Current Availability Landscape (2026)

Calcium acetate generics are produced by multiple manufacturers and are broadly available in the drug supply chain. The national stock level is adequate. However, localized distribution gaps persist due to several factors:

High unit demand per patient (200–400 tablets/capsules per month at typical dosing of 3–4 tablets per meal)

Brand-specific prescribing patterns that restrict substitution at the pharmacy level

Limited availability of the oral solution (Phoslyra 667 mg/5 mL) at standard retail pharmacies

Inconsistent stocking at rural and independent pharmacies

Clinical Implications of Missed Doses

Dialysis patients who miss calcium acetate doses are at risk for acute phosphate spikes between dialysis sessions. The consequences of sustained hyperphosphatemia include:

Secondary hyperparathyroidism and renal osteodystrophy

Ectopic calcification in soft tissues and blood vessels

Increased cardiovascular mortality risk

Pruritus and calciphylaxis in severe cases

Even short interruptions in phosphate binder therapy can lead to measurable increases in serum phosphate. Early intervention is essential.

Evidence-Based Alternatives When Calcium Acetate Is Unavailable

When calcium acetate cannot be sourced in a timely manner, the following evidence-based alternatives should be considered. Patient-specific factors — including serum calcium, serum phosphate, PTH levels, iron stores, and cardiovascular risk — should guide the selection.

Sevelamer carbonate (Renvela): Non-calcium polymer binder; preferred in patients with hypercalcemia or a high calcium-phosphate product. Some evidence supports reduced cardiovascular mortality vs. calcium-based binders. Generic available. High pill burden (up to 12 tablets/day). For switching from calcium acetate, dose conversion tables are available in the Renvela prescribing information.

Lanthanum carbonate (Fosrenol): Non-calcium binder; lower pill burden than sevelamer; FDA-approved since 2004. Minimally absorbed; eliminated via hepatobiliary pathway. Suitable for patients with hypercalcemia or difficulty tolerating sevelamer GI side effects.

Ferric citrate (Auryxia): Iron-based binder; dual benefit in patients with concurrent iron-deficiency anemia. Phase 3 trial data showed non-inferiority to sevelamer. High cost may be a barrier; GI side effects (dark stools, nausea) common.

Sucroferric oxyhydroxide (Velphoro): Iron-based chewable tablet; lower pill burden than sevelamer; calcium-free. Suitable for patients with compliance challenges related to pill count. Higher cost than generic calcium acetate.

Prescribing Strategies to Prevent Supply Interruptions

The following prescribing practices can meaningfully reduce the frequency with which your patients experience supply disruptions:

Write "calcium acetate 667 mg — dispense generic if available" rather than specifying a brand name. This gives pharmacies maximum flexibility to fill the prescription.

Prescribe 90-day supplies via mail-order pharmacy when possible. This reduces refill frequency and gives patients a larger buffer supply.

Direct patients to dialysis center-affiliated pharmacies that maintain dedicated stock of phosphate binders. These specialty pharmacies are significantly more reliable than general retail locations.

Recommend medfinder to patients who struggle with pharmacy access. This paid service calls pharmacies to find which ones have medications in stock and texts the patient the results.

38,179+ patients found their medications in stock

38K+

Find Calcium Acetate In Stock Today →

Monitoring After a Phosphate Binder Switch

If you switch a patient from calcium acetate to a non-calcium binder, plan to recheck serum phosphate and calcium within 2–4 weeks. Patients accustomed to the calcium load from calcium acetate may see changes in serum calcium and PTH after switching. Additionally, when switching to sevelamer, dose titration is recommended per the package insert conversion chart (Renvela Prescribing Information, Table 3).

How medfinder Helps Your Patients

medfinder is a paid service that calls pharmacies in a patient's area to determine which ones have a specific medication in stock. Patients provide their medication, dosage, and ZIP code — medfinder does the calling and texts them results. Providers can learn more about recommending medfinder to patients at medfinder.com/providers. For a step-by-step guide on helping your patients locate calcium acetate, see our provider guide to helping patients find calcium acetate.